Shares shifted sharply lower as STAAR Surgical, the maker of implantable vision-correction lenses, dropped 11% to $25.79 after its preliminary Q2 revenue topped $90 million — more than double the $44.3 million posted in Q2 2025 — yet merely matched the Street's ~$90.2 million consensus. The stock had run up roughly 70% over the prior year, meaning the good news was already priced in and investors who bought the turnaround story cashed out.
• Doubling Revenue Means Nothing When Expectations Already Got There First. STAAR's preliminary Q2 revenue implied year-over-year growth of more than 103%, and the figure came in ahead of Canaccord's $88.4 million estimate but in-line with consensus of $90.2 million. That gap between "beating some analysts" and "merely matching the crowd" was enough to trigger a classic sell-the-news reaction. For shareholders, the lesson is blunt: this stock needs upside surprises — not confirmations — to sustain its valuation.
• An ERP Headache Raises Questions About the Profit Picture. Co-CEO Warren Foust acknowledged that the company's new enterprise software system "presented meaningful operational challenges during the quarter."
Management said it remains focused on resolving the remaining system issues in the third quarter. ERP disruptions often inflate costs and slow order processing — a risk that matters greatly for a company still reporting negative earnings per share of -$0.42 and trying to return to profitability.
• A Leadership Vacuum and No Formal Guidance Keep Investors Guessing. STAAR has been run by interim co-CEOs since February 2026, after its board appointed Warren Foust and Deborah Andrews while a global search for a permanent CEO continues.
Canaccord noted it would like to see "firmer footing on permanent management and the reinstatement of formal financial guidance." Without a named leader or official forecast, Wall Street is pricing in uncertainty — a discount that won't lift until those gaps close.
• Regional Risks Could Cap the Rebound. Growth was led by sequential gains in China and double-digit expansion in the Americas, but EMEA sales declined on a low single-digit basis, reflecting ongoing turmoil in the Middle East.
STAAR cautioned that if current headwinds persist or worsen, sales growth could continue to be negatively affected — and that a broadening of macroeconomic challenges to additional regions could also hurt future results. With six of eleven covering analysts rating the stock Hold and two rating it Sell , the consensus view is that STAAR must prove its turnaround extends beyond a favorable China comparison before the stock deserves a higher price.